Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Colorectal Neoplasms 150Stomach Neoplasms 52Neoplasms 49Pancreatic Neoplasms 41Neoplasm Metastasis 32Squamous Cell Carcinoma of Head and Neck 26Head and Neck Neoplasms 25Esophageal Neoplasms 24Colonic Neoplasms 22Rectal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Esophageal Squamous Cell Carcinoma 15Adenocarcinoma 14Adenocarcinoma Of Esophagus 12Cholangiocarcinoma 11Biliary Tract Neoplasms 11Ovarian Neoplasms 9Triple Negative Breast Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Urinary Bladder Neoplasms 6Sarcoma 6Keratosis, Actinic 6Gastrointestinal Neoplasms 6Endometrial Neoplasms 6Carcinoma, Squamous Cell 6Advanced Solid Tumors 6

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × Fluorouracil × Clear all
NCT02715531 2021-07-09

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
243 enrolled
Other solid neoplasm

Solid Tumor

NCT02884128 2016-08-30

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

PharmaEngine

Phase 1 Completed
16 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡